| Prev Close: | 52.65 |
|---|---|
| Open: | 52.81 |
| Bid: | 52.90 x 100 |
| Ask: | 53.35 x 300 |
| 1y Target Est: | 48.56 |
| Beta: | 0.57 |
| Next Earnings Date: | N/A |
| Day's Range: | 52.81 - 53.45 |
|---|---|
| 52wk Range: | 41.68 - 53.45 |
| Volume: | 2,517,000 |
| Avg Vol (3m): | 2,761,320 |
| Market Cap: | 128.22B |
| P/E (ttm): | 19.35 |
| EPS (ttm): | 2.74 |
| Div & Yield: | 2.20 (4.20%) |
Headlines
- Data on UCB's NeuproZacks(Wed 4:25PM EDT)
- XenoPort Resumes Horizant SupplyZacks(Wed 4:20PM EDT)
- Glaxo, US partnering to develop new antibioticsAP(Wed 2:27PM EDT)
- [video] Benefiting From the Rotation To Cyclicalsat TheStreet(Wed 11:42AM EDT)
- 3 Reasons to Love GlaxoSmithKlineat Motley Fool(Wed 11:21AM EDT)
- [video] New Home Demand Drives Tollat TheStreet(Wed 11:06AM EDT)
- The 5 Highest-Paying Dividend Stocks in Big Pharmaat Motley Fool(Wed 11:06AM EDT)
- Toll Reports Better-than-Expected Earnings: Ahead of the Tickerat TheStreet(Wed 9:55AM EDT)
- Is Merck a Buy at These Prices?at Wall St. Cheat Sheet(Wed 8:43AM EDT)
- XenoPort Candidate DisappointsZacks(Tue, May 21)
- Elan Provides Strategic UpdateZacks(Tue, May 21)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue, May 21)
- What Are the City's Expectations for GlaxoSmithKline's Profits?at Motley Fool(Tue, May 21)
- New Home Demand Drives TollTheStreet.com TV(Tue, May 21)
- GlaxoSmithKline Stock Hits New 52-Week High (GSK)at TheStreet(Tue, May 21)
Press Releases
- From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic ResearchersBusiness Wire(Tue, May 21)
- BREO™ ELLIPTA™ gains US approval for the treatment of COPDPR Newswire(Fri, May 10)
- BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPDMarketwired(Fri, May 10)
Reports
- ValuEngine Industry Report for Large CAP PharmaValuEngine, Inc.(May 22)
- Market Edge Equity Research ReportMarket Edge(May 20)
- GlaxoSmithKline plc ADSS&P Capital IQ – STARS Reports(May 18)
